ReviewNPJ cardiovascular health2026
Drug-coated balloon angioplasty in coronary artery disease: state of the art review.
Review in NPJ cardiovascular health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Navigating Ischemic and Bleeding Risks in High Bleeding Risk Patients Undergoing Coronary Intervention.Cardiology research · 2026Review
- Robotic Coronary Artery Bypass Grafting: A Narrative Review of Techniques, Evidence, and Future Directions.Journal of clinical medicine · 2026Review
- Acute Coronary Syndrome and Recreational Drug Use: A Comprehensive Review.Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-coated balloons (DCBs) provide a "leave-nothing-behind" revascularization strategy, delivering antiproliferative therapy without permanent implants. This review presents evidence on DCB performance across coronary indications. In in-stent restenosis and de novo disease, DCBs are associated with higher rates of repeat revascularization compared to drug-eluting stents (DES). In small vessel disease, DCBs achieve comparable or sometimes superior outcomes. In complex lesions or high-risk patients, dedicated studies demonstrate feasibility and signals of non-inferiority.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.